Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Milan
Clinical trial register · Italy

Clinical Trials in Milan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 51 Bologna 30 Roma 25 Florence 25 Naples 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
IRCCS San Raffaele160 AstraZeneca138 Merck Sharp & Dohme LLC98 Hoffmann-La Roche81 Novartis Pharmaceuticals73 Clear sponsor filter
Site location
Milan51 Bologna30 Roma25 Florence25 Naples22
All 68 locations
Target enrolment
to

Trials with a site in Milan

51 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Eli Lilly and Company
Phase 3
170
Ancona, Florence, Genova, Messina, Milan, Naples, Verona
2026-09
Recruiting
Eli Lilly and Company
Phase 2
600
Genova, Milan, Misterbianco, Prato, Roma
2026-05-13
Recruiting
Eli Lilly and Company
Phase 2
60
Florence, Milan, Monza, Negrar, Roma, Rozzano
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Florence, Milan, Monza, Negrar, Roma, Rozzano
2026-05-04
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Bologna, Milan
2026-04-17
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Milan, Rho, Rome, Rozzano
2026-03-26
Recruiting
Eli Lilly and Company
Phase 3
150
Ancona, Bologna, Cagliari, Florence, Milan, Naples, Novara, Padova
2026-01-12
Recruiting
Eli Lilly and Company
Phase 3
800
Bergamo, Bologna, Florence, Genova, Meldola, Milan, Misterbianco, Monza
2025-12-22
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Bari, Milan, Naples, Padova, Pisa, Roma, Rome
2025-12-12
Recruiting
Eli Lilly and Company
Phase 3
7,140
Bologna, Brescia, Ferrara, Florence, Genova, Milan, Monza, Palermo
2025-12-01
Recruiting
Eli Lilly and Company
Phase 2
252
Milan, Roma, Rozzano
2025-11-10
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bologna, Catania, Lecce, Lucca, Milan, Modena, Naples, Prato
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
4,500
Bergamo, Bologna, Florence, Milan, Naples, Padova, Palermo, Roma
2025-10-15
Recruiting
Eli Lilly and Company
Phase 1/2
68
Bologna, Milan, Roma, Trieste
2025-07-30
Recruiting
Eli Lilly and Company
Phase 3
290
Bologna, Castellana Grotte, Milan, Padova, Pisa, Rho, Roma, Rozzano
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
Bologna, Castellana Grotte, Milan, Padova, Pisa, Rho, Roma, Rozzano
2025-06-26
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Bologna, Milan
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Bologna, Milan
2025-05-20
Active, closed
Eli Lilly and Company
Phase 3
905
Bologna, Catanzaro, Florence, Milan, Naples, Padova, Roma, Torino
2025-04-25
Recruiting
Eli Lilly and Company
Phase 3
700
Bari, Catania, Genova, Meldola, Milan, Monza, Naples, Orbassano
2025-03-27
Active, closed
Eli Lilly and Company
Phase 2
45
Milan, Naples, Rome
2024-10-25
Active, closed
Eli Lilly and Company
Phase 2
143
Bologna, Brescia, Fano, Florence, Gazzi - Messina, Milan, Modena, Monserrato
2024-10-10
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Milan
2024-05-20
Active, closed
Eli Lilly and Company
Phase 3
10,000
Bologna, Ferrara, Genova, Milan, Palermo, Perugia, Pisa, Roma
2024-04-30
Recruiting
Eli Lilly and Company
Phase 3
510
Florence, Milan, Naples, Padova, Pisa, Rome, Vimercate
2024-04-29
Recruiting
Eli Lilly and Company
Phase 3
90
Alessandria, Bergamo, Bologna, Florence, Milan, Roma
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
17,300
Arzignano, Baggiovara, Bologna, Cinisello Balsamo, Ferrara, Florence, Genova, Milan
2024-03-05
Recruiting
Eli Lilly and Company
Phase 3
1,264
Bari, Bologna, Catania, Milan, Naples, Padova, Roma, Rome
2023-12-21
Recruiting
Eli Lilly and Company
Phase 1/2
880
Alessandria, Brescia, Milan, Monza, Pisa, Ravenna, Roma, Verona
2023-04-17
Recruiting
Eli Lilly and Company
Phase 1
677
Milan, Roma
2023-01-12
Active, closed
Eli Lilly and Company
Phase 3
8,000
Ancona, Bergamo, Bologna, Brindisi, Candiolo, Florence, Genova, Milan
2022-10-04
Active, closed
Eli Lilly and Company
Phase 4
780
Bari, Naples, Milan, Moncalieri, Olbia, Palermo, Pisa, Catanzaro
2022-08-01
Active, closed
Eli Lilly and Company
Phase 3
925
Meldola, Rome, Milan, Castelfranco Veneto, Terni, Trento
2022-04-14
Active, closed
Eli Lilly and Company
Phase 3
368
Misterbianco, Meldola, Udine, Bari, Grosseto, Milan, Viterbo
2022-03-11
Active, closed
Eli Lilly and Company
Phase 3
152
Bari, Milan, Rozzano, Naples, Orbassano, Padova
2021-12-20
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Bergamo, Bologna, Florence, Milan, Roma, Rome
2021-05-26
Active, closed
Eli Lilly and Company
Phase 3
101
Naples, Genoa, Milan, Florence, Brescia
2021-04-13
Active, closed
Eli Lilly and Company
Phase 3
312
Milan, Roma
2020-11-25
Active, closed
Eli Lilly and Company
Phase 3
996
Milan, Rho
2020-06-22
Active, closed
Eli Lilly and Company
Phase 1
71
Milan
2020-06-11
Active, closed
Eli Lilly and Company
Phase 3
261
Naples, Ravenna, Aviano, Rome, Monza, Milan, Rozzano, Orbassano
2020-02-17
Active, closed
Eli Lilly and Company
Phase 3
58
Brescia, Chieti, Genova, Milan, Naples, Palermo, Trieste
2020-02-12
Recruiting
Eli Lilly and Company
Phase 2
105
Bologna, Candiolo, Milan, Padova, Roma, Rozzano
2020-01-22
Active, closed
Eli Lilly and Company
Phase 3
30
Milan, Florence
2019-10-16
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
Milan
2019-06-13
Recruiting
Eli Lilly and Company
Phase 3
190
Brescia, Chieti, Genova, Milan, Naples, Palermo, Trieste
2019-04-05
Active, closed
Eli Lilly and Company
Phase 3
533
Milan, Roma
2018-03-14
Active, closed
Eli Lilly and Company
Phase 3
5,637
Naples, Cona, Meldola, Monza, Milan, Rozzano, Rome, Terni
2017-07-12
Active, closed
Eli Lilly and Company
Phase 1/2
857
Milan
2017-05-02
Active, closed
Eli Lilly and Company
Phase 1
100
Meldola, Milan
2016-11-14
Active, closed
Eli Lilly and Company
Phase 3
545
Bari, Aviano, Orbassano, Bologna, Milan, Padova
2015-05-06
Rows per page Showing 1–51 of 51
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/milan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 51 of those studies with a site in Milan that also match the filters currently applied.

How many clinical trials are recruiting in Milan?

27 of the 51 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 23 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Milan), 51 studies
PhaseStudiesRecruitingShare
Phase 3311460.8%
Phase 28615.7%
Phase 1539.8%
Phase 1/2427.8%
Phase 4325.9%

Most active sponsors

Lead sponsors with the most studies (Milan)
Lead sponsorStudiesRecruiting
Eli Lilly and Company5127
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.